JP7545726B2 - tRNA/プレmiRNA組成物およびがん治療における使用 - Google Patents

tRNA/プレmiRNA組成物およびがん治療における使用 Download PDF

Info

Publication number
JP7545726B2
JP7545726B2 JP2020564923A JP2020564923A JP7545726B2 JP 7545726 B2 JP7545726 B2 JP 7545726B2 JP 2020564923 A JP2020564923 A JP 2020564923A JP 2020564923 A JP2020564923 A JP 2020564923A JP 7545726 B2 JP7545726 B2 JP 7545726B2
Authority
JP
Japan
Prior art keywords
mir
hsa
rna
trna
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020564923A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021524245A5 (cg-RX-API-DMAC7.html
JP2021524245A (ja
Inventor
エイミン ユ、
プイ ヤン ホ、
メイジャン ツ、
ジョセフ エル. ジレク、
キャンユ ツァン、
ハンナ イー. ペトレク、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California, San Diego
Original Assignee
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, San Diego filed Critical University of California, San Diego
Publication of JP2021524245A publication Critical patent/JP2021524245A/ja
Publication of JP2021524245A5 publication Critical patent/JP2021524245A5/ja
Application granted granted Critical
Publication of JP7545726B2 publication Critical patent/JP7545726B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020564923A 2018-05-22 2019-05-21 tRNA/プレmiRNA組成物およびがん治療における使用 Active JP7545726B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862674939P 2018-05-22 2018-05-22
US62/674,939 2018-05-22
PCT/US2019/033232 WO2019226603A1 (en) 2018-05-22 2019-05-21 Trna/pre-mirna compositions and use in treating cancer

Publications (3)

Publication Number Publication Date
JP2021524245A JP2021524245A (ja) 2021-09-13
JP2021524245A5 JP2021524245A5 (cg-RX-API-DMAC7.html) 2022-05-23
JP7545726B2 true JP7545726B2 (ja) 2024-09-05

Family

ID=68616101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020564923A Active JP7545726B2 (ja) 2018-05-22 2019-05-21 tRNA/プレmiRNA組成物およびがん治療における使用

Country Status (4)

Country Link
US (1) US11946049B2 (cg-RX-API-DMAC7.html)
EP (1) EP3796920A4 (cg-RX-API-DMAC7.html)
JP (1) JP7545726B2 (cg-RX-API-DMAC7.html)
WO (1) WO2019226603A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019204733A1 (en) * 2018-04-20 2019-10-24 The Regents Of The University Of California tRNA/pre-miRNA COMPOSITIONS AND METHODS FOR TREATING HEPATOCELLULAR CARCINOMA
GB201919021D0 (en) 2019-12-20 2020-02-05 Reneuron Ltd Nucleic acid constructs for delivering polynucleotides into exosomes
CN110946872B (zh) * 2019-12-30 2022-11-04 北京大学深圳医院 miR-4491在制备治疗乳腺癌的药物中的应用
BR112022020780A2 (pt) * 2020-04-14 2022-11-29 Flagship Pioneering Innovations Vi Llc Composições de trem e usos das mesmas
CN114058697B (zh) * 2020-07-29 2023-08-18 四川大学华西医院 检测外泌体miR-6774-3p或miR-6776-5p的试剂的用途
WO2022098788A1 (en) * 2020-11-03 2022-05-12 The Regents Of The University Of California Bioengineered wnt5a therapeutics for advanced cancers
US20230416758A1 (en) * 2020-11-23 2023-12-28 Thomas Jefferson University Trna fragments and methods of use
US20240327830A1 (en) * 2022-02-28 2024-10-03 Northwestern University Dise-inducing srna-polyplexes and srna-lipopolyplexes and methods of using the same to treat cancer
IL318039A (en) * 2022-07-10 2025-02-01 Precigen Inc Polycistronic microRNA constructs for immune checkpoint inhibition
CN115323057A (zh) * 2022-09-01 2022-11-11 浙江医院 肺癌治疗疗效相关的生物标志物
CN115896295A (zh) * 2022-12-30 2023-04-04 中国科学技术大学 辅助诊断胆囊炎或预测胆囊炎合并肝损伤的miRNA标志物
CN117126938A (zh) * 2023-10-08 2023-11-28 常州市第一人民医院 一种用于诊断膜性肾病的生物标志物及其应用方法
WO2025155837A1 (en) * 2024-01-19 2025-07-24 Massachusetts Institute Of Technology Modular microrna expression from self-replicating rna (replicons)
CN121406635A (zh) * 2024-05-08 2026-01-27 西安艾领克生物科技有限公司 一种利用活性tRNA在大肠杆菌中嵌合表达重组小RNA的方法及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523856A (ja) 2012-05-25 2015-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ Rna依存性標的dna修飾およびrna依存性転写調節のための方法および組成物
JP2016533760A (ja) 2013-09-06 2016-11-04 プレジデント アンド フェローズ オブ ハーバード カレッジ スイッチ可能cas9ヌクレアーゼおよびその使用
JP2017524341A (ja) 2014-05-28 2017-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ハイブリッドtRNA/プレmiRNA分子および使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016153880A2 (en) 2015-03-23 2016-09-29 The Regents Of The University Of California Methods for detection of rnase activity
WO2019204733A1 (en) 2018-04-20 2019-10-24 The Regents Of The University Of California tRNA/pre-miRNA COMPOSITIONS AND METHODS FOR TREATING HEPATOCELLULAR CARCINOMA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015523856A (ja) 2012-05-25 2015-08-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ Rna依存性標的dna修飾およびrna依存性転写調節のための方法および組成物
JP2016533760A (ja) 2013-09-06 2016-11-04 プレジデント アンド フェローズ オブ ハーバード カレッジ スイッチ可能cas9ヌクレアーゼおよびその使用
JP2017524341A (ja) 2014-05-28 2017-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ハイブリッドtRNA/プレmiRNA分子および使用方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. Pharmacol. Exp. Ther.,Vol.365,p.494-506,Epub 2018.03.30

Also Published As

Publication number Publication date
US11946049B2 (en) 2024-04-02
EP3796920A1 (en) 2021-03-31
US20210246446A1 (en) 2021-08-12
JP2021524245A (ja) 2021-09-13
EP3796920A4 (en) 2023-03-01
WO2019226603A1 (en) 2019-11-28

Similar Documents

Publication Publication Date Title
US11946049B2 (en) tRNA/pre-miRNA compositions and use in treating cancer
US10619156B2 (en) Hybrid tRNA/pre-miRNA molecules and methods of use
US10612026B2 (en) Pharmaceutical composition for treating cancer comprising microrna as active ingredient
US11602568B2 (en) Engineered B lymphocytes and compositions having micro-RNA and methods for making and using them
EP2208499A1 (en) Nucleic acid capable of regulating the proliferation of cell
US20140080894A1 (en) Enhanced biodistribution of oligomers
US20110152352A1 (en) Smad proteins control drosha-mediated mirna maturation
EP3500244A1 (en) Methods of suppressing delivery of exosomes to liver and spleen
US11041201B2 (en) Methods for detection of RNase activity
US11519008B2 (en) Exosome delivery system
US11702657B2 (en) TRNA/pre-miRNA compositions and methods for treating hepatocellular carcinoma
Ho Bioengineering ncRNAs for Biomedical Research and Therapy
WO2022098788A1 (en) Bioengineered wnt5a therapeutics for advanced cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220513

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220513

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240520

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240723

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240819

R150 Certificate of patent or registration of utility model

Ref document number: 7545726

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150